Clinical Computing PLC
12 June 2001
For Immediate Release, 12 June 2001
CLINICAL COMPUTING, PLC:
CONTRACT GAIN
Clinical Computing PLC and Independent Dialysis Foundation, Inc.:
Agreement to Purchase Clinical Vision/Renal Vision clinical software
Clinical Computing, Plc., (CCL) the international provider of clinical
software solutions for the renal dialysis market, announces that its
wholly-owned US subsidiary, Clinical Computing, Inc. (CCI) has signed a
contract for the delivery of its Clinical Vision/Renal VisionTM software for
general testing in the US with Independent Dialysis Foundation, Inc. (IDF) in
Baltimore, Maryland.
Clinical Vision/Renal Vision is the third generation renal software solution
from Clinical Computing and is the result of a three-year development effort.
Clinical Vision, like its predecessors (PROTONTM, di-PROTONTM) was developed
to deliver future resistant value with technologies that are ahead of its
competition. In addition to serving the renal marketplace, Clinical Vision is
designed to extend into other clinical applications such as solid organ
transplantation.
IDF is a leading provider of End Stage Renal Disease treatments in the
Baltimore area and is led by Dr. John Sadler, a nationally known Nephrologist.
IDF provides hemodialysis to over 500 patients in ten facilities throughout
Maryland.
Tracey Mooney, CPA, Chief Financial Officer of IDF, said:
'Clinical Computing demonstrates their strength as a company through their
responsiveness and by incorporating our suggestions into their go-forward
strategy. Our experience with the Clinical Vision product is that it is easy
to learn and user friendly.'
Under the agreement, CCI will deliver its comprehensive clinical software for
the renal market on multiple platforms including Windows, Web and PDAs. IDF
will utilize the system to provide comprehensive charting, patient data
analysis and to automate charge capture, resulting in a seamless blending of
clinical vision and fiscal operations.
The product was installed in the first week of May, 2001 and will be tested in
a clinical setting for 60 days, commencing in June of 2001.
END
Press Enquiries:
Clinical Computing Plc
Tim Klenke, Vice President, Sales and Marketing, North America
Tel: 513-651-3803 x 130
Binns & Co PR Ltd
Peter Binns, James Horsman
Tel: +44 (0)20 7786 9600
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.